CRDL
Cardiol Therapeutics Inc.·Healthcare
1.38
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.8852W H: $1.59
CRDL NEWS
newsfilecorp.com
Apr 1
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure.
defenseworld.net
Mar 10
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
Cardiol Therapeutics (NASDAQ: CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its clinical development programs targeting inflammation in cardiac disease, with its most advanced asset, CardiolRx, currently being studied in a Phase III trial for recurrent pericarditis. Focus on inflammation across cardiac indications CEO David Elsley said the company is focused
newsfilecorp.com
Feb 25
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m.
newsfilecorp.com
Feb 10
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol's lead oral drug candidate, in 109 patients with acute myocarditis using advanced cardiac magnetic resonance (CMR) imaging measures of myocardial inflammation and remodelling.
defenseworld.net
Feb 6
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?
Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during mid-day trading on Thursday. The stock traded as low as C$1.30 and last traded at C$1.31. 101,594 shares traded hands during trading, an increase of 34% from the average session volume of 75,629 shares. The stock had previously closed at C$1.41. Cardiol
defenseworld.net
Feb 6
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – What’s Next?
Cardiol Therapeutics Inc. (TSE: CRDL - Get Free Report) shares fell 7.1% during trading on Thursday. The stock traded as low as C$1.30 and last traded at C$1.31. 101,594 shares were traded during mid-day trading, an increase of 34% from the average session volume of 75,629 shares. The stock had previously closed at C$1.41. Cardiol
